World Pharma AIRegister

All insights

Markets

Merck hands Isomorphic Labs its own data to design drugs for an undisclosed cancer target

Isomorphic will deliver designs from its IsoDDE engine while Merck runs development, with milestones, royalties and a co-funding option.

By World Pharma AI Editorial2 min read2 sources

Merck and Isomorphic Labs said on 19 November 2026 that they will work together to find small molecule drug candidates against a single oncology target, which neither company has named1. Merck, known as MSD outside the US and Canada, called it a target of strategic importance to the company1.

How the work is split

Isomorphic Labs will run the computational side. It will make in silico predictions and hand over molecular designs produced by its drug design engine, IsoDDE, which for this programme will draw on selected proprietary data sets that Merck supplies1. Merck takes everything downstream: preclinical and clinical development, manufacturing and commercialisation of any product that emerges1.

Merck will pay Isomorphic Labs an upfront sum, with further payments tied to research, development, regulatory and commercial milestones, plus tiered royalties on net sales1. Isomorphic Labs also holds an option to co-fund development in exchange for higher royalties1. Neither the release nor the published report gives any of the amounts12.

George Addona, who leads discovery, preclinical development and translational medicine at Merck Research Laboratories, told STAT that Merck has already run internal work on the target and that “the pairing of those datasets with the Isomorphic drug discovery engine technology could be a very powerful pairing”2. In the company statement he said the key to using AI and machine learning for molecular invention “lies in close coordination of wet-lab and dry-lab functions”1.

What it means for the market

The structure is the point for R&D leaders. Merck is not licensing a finished asset; it is giving an outside AI designer access to its own wet lab data on a target it has already worked on, and keeping full control of development and sales12. That makes the proprietary data a large pharma company holds part of what it brings to the table, alongside cash.

For Isomorphic Labs, the co-funding option gives it a route to a larger share of any product's economics without carrying a clinical programme alone1. STAT described the agreement as only the latest such deal between Isomorphic and a large drugmaker2. Isomorphic Labs, founded in 2021 and led by chief executive Sir Demis Hassabis, is based in London with offices in Cambridge, Massachusetts and Lausanne, and runs both partnered and wholly owned programmes1.

For rival AI drug designers, the deal adds another large drugmaker to Isomorphic's partner list, but with no disclosed terms it sets no price benchmark12.

Caveats

The financial value of the agreement is undisclosed, as is the target1. The collaboration covers discovery only, and Merck's own statement notes there can be no guarantee that pipeline candidates will win regulatory approval or succeed commercially1. Any candidate would still need to pass Merck's preclinical work before reaching patients1.

Sources

  1. Merck and Isomorphic Labs Enter Strategic Research Collaboration (opens in a new tab)Merck · merck.com
  2. Merck, Isomorphic Labs partner to develop oncology drug candidates (opens in a new tab)STAT · statnews.com

This briefing summarises publicly available research and reporting for information only. It is not medical, investment or legal advice. Follow the sources listed for the primary research and reporting.